Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.201 | uM | 9860.011 | 0.8348 | 0.7677 | 1.4618 | |
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 1.01 | uM | 9860.011 | 0.7286 | 0.6106 | 1.4618 | |
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 5.03 | uM | 9860.011 | 0.6043 | 0.4170 | 1.4618 | |
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 25.2 | uM | 9860.011 | 0.2542 | -0.2165 | 1.4618 | |
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 126 | uM | 9860.011 | 0.2705 | -0.1823 | 1.4618 | |
| SUM229PE | TNBC | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 9860.011 | 0.1862 | -0.3668 | 1.4618 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00161 | uM | 9878.011 | 1.1489 | 1.2265 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00805 | uM | 9878.011 | 1.1088 | 1.1661 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.0403 | uM | 9878.011 | 1.1382 | 1.2105 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.201 | uM | 9878.011 | 0.8948 | 0.8353 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 1.01 | uM | 9878.011 | 0.8674 | 0.7918 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 5.03 | uM | 9878.011 | 0.7325 | 0.5722 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 25.2 | uM | 9878.011 | 0.4398 | 0.0600 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 126 | uM | 9878.011 | 0.0657 | -0.7563 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 9878.011 | 0.0236 | -0.8894 | 1.2938 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00161 | uM | 9889.021 | 1.0337 | 1.0478 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00805 | uM | 9889.021 | 0.9859 | 0.9799 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.0403 | uM | 9889.021 | 1.0073 | 1.0104 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.201 | uM | 9889.021 | 0.9156 | 0.8781 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 1.01 | uM | 9889.021 | 0.7969 | 0.7010 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 5.03 | uM | 9889.021 | 0.5644 | 0.3298 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 25.2 | uM | 9889.021 | 0.2741 | -0.2056 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 126 | uM | 9889.021 | 0.0764 | -0.6807 | 1.4017 | |
| SUM52PE | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 9889.021 | 0.0386 | -0.8038 | 1.4017 | |
| T47D | HR+ | Luminal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 0.00161 | uM | 9033.075 | 0.9690 | 0.9352 | 0.9560 |